Transgene【TNG】銘柄情報

リアルタイムのディスカッションと取引のアイデア: 当社の強力なプラットフォームで自信を持って取引できます。

プレミアム

通貨

0.788

買値

0.781

売値

0.788

出来高

14,944

0.78 日の範囲 0.80

0.76 52 週間の範囲 1.52

時価総額

79.472M

前日終値

0.782

始値

0.79

時刻

0.788

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

34,859

発行済株式数

100,852,742

配当利回り

PER

-3.57

1 株当たり利益 (EPS)

-0.22

歳入

7.9M

純利益

-22.33M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.transgene.fr

本社

Illkirch-graffenstaden, Bas-rhin, Fra

設立

Transgene SA is listed in the Pharmaceutical Preparations sector of the ユーロネクスト with ticker TNG. The last closing price for Transgene was 0.78 €. Over the last year, Transgene shares have traded in a share price range of 0.76 € to 1.52 €.

Transgene currently has 100,852,742 shares in issue. The market capitalisation of Transgene is 78.87 € million. Transgene has a price to earnings ratio (PE ratio) of -3.57.

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024

Transgene et NEC présentent de nouvelles données confirmant la preuve de principe clinique pour son vaccin thérapeutique TG4050, dans les cancers de la tête et du cou au SITC 2024 Les données de...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced...

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024 Compelling 24.1-month median follow-up data...

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers Top line data show that the randomized...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.05	-5.96658711217	0.838	0.838	0.76	29161	0.78748416	DE
4	-0.138	-14.9028077754	0.926	0.964	0.76	40513	0.86634154	DE
12	-0.34	-30.1418439716	1.128	1.204	0.76	34859	0.98604941	DE
26	-0.536	-40.4833836858	1.324	1.35	0.76	30040	1.05785457	DE
52	-0.662	-45.6551724138	1.45	1.52	0.76	29773	1.17604595	DE
156	-1.622	-67.3029045643	2.41	2.99	0.76	38046	1.92820697	DE
260	-1.022	-56.4640883978	1.81	3.15	0.76	74399	1.98395186	DE

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
MLAAHAmatheon Agri Holding NV	0.02 € (100.00%)	5k
GNROGeNeuro SA	0.0768 € (25.49%)	200
BIDSGascogne DS	0.005 € (25.00%)	150.51k
ALSAFSAFE	0.11 € (23.73%)	39.98k
ALKKOKKO International SA	0.112 € (21.21%)	4.13M
ALIMOGroupimo	0.189 € (-40.94%)	392
MLUMGUmalis Group	1.30 € (-31.22%)	1.71k
MLNMAMiguet Et Associes	0.075 € (-24.62%)	1.72k
MLSEQSequa Petroleum NV	0.008 € (-20.00%)	23k
VACBSPierre & Vacances	0.05 € (-15.25%)	35.99k
BCPBanco Comercial Portugues SA	0.4446 € (-0.49%)	69.24M
ALNEVNeovacs	0.0002 € (0.00%)	41.4M
ALCYBCybergun	0.0001 € (0.00%)	30.32M
INGAING Groep NV	14.652 € (-1.16%)	14.06M
ACACredit Agricole SA	13.05 € (-1.66%)	8.06M